Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
mergers and acquisitions
Pharma
2025's top biopharma M&A deals
Looming patent expirations and a thawing of the biotech investment scene prompted drug developers of all stripes to pull out their checkbooks in 2025.
Fraiser Kansteiner
,
Zoey Becker
,
Angus Liu
,
Kevin Dunleavy
,
Eric Sagonowsky
,
Andrea Park
Jan 12, 2026 3:00am
Sanofi bolsters adult vaccine roster with $2.2B Dynavax purchase
Dec 29, 2025 10:24am
2024's top biopharma M&A deals
Brought to you by
Pfizer
Does the Q4 M&A binge foreshadow a boom year for deals in 2026?
Dec 24, 2025 5:00am
NanoVibronix rebrand feeds into new focus on ENvue system
Dec 12, 2025 11:00am
Omnicom Health names IPG Health’s Dana Maiman CEO
Dec 1, 2025 11:09am
